Novartis' Entresto: Slow Uptake Expected Following Fast FDA Approval
Reimbursement complexity and physician reluctance to move stable patients off their current treatment regimens are the biggest hurdles.
Reimbursement complexity and physician reluctance to move stable patients off their current treatment regimens are the biggest hurdles.